Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Debt to Equity (2017 - 2024)

Organogenesis Holdings has reported Debt to Equity over the past 8 years, most recently at $0.22 for Q3 2024.

  • For Q3 2024, Debt to Equity fell 8.67% year-over-year to $0.22; the TTM value through Sep 2024 reached $0.22, down 8.67%, while the annual FY2023 figure was $0.24, 10.78% down from the prior year.
  • Debt to Equity for Q3 2024 was $0.22 at Organogenesis Holdings, down from $0.24 in the prior quarter.
  • Over five years, Debt to Equity peaked at $1.45 in Q2 2020 and troughed at $0.19 in Q2 2021.
  • A 5-year average of $0.36 and a median of $0.27 in 2022 define the central range for Debt to Equity.
  • On a YoY basis, Debt to Equity climbed as much as 61.8% in 2021 and fell as far as 87.13% in 2021.
  • Year by year, Debt to Equity stood at $0.19 in 2020, then surged by 61.8% to $0.3 in 2021, then dropped by 12.45% to $0.27 in 2022, then fell by 10.78% to $0.24 in 2023, then fell by 6.17% to $0.22 in 2024.
  • Business Quant data shows Debt to Equity for ORGO at $0.22 in Q3 2024, $0.24 in Q2 2024, and $0.23 in Q1 2024.